2 days Ago By ABMN Staff
Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS – Free Report ) – HC Wainwright reduced their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst D.
Tsao now expects that the company will post earnings of ($1.79) per share for the year, down from their previous forecast of ($1.67).
HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.
50) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.
55) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.
37) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at $0.
88 EPS and FY2028 earnings at $2.61 EPS. APLS has been the topic of a number of other research reports.
Bank of America decreased their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research report on Wednesday.
Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. decreased their price target on Apellis Pharmaceuticals from $64.
00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Scotiabank cut their price objective on Apellis Pharmaceuticals from $35.
00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.
00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.06. Apellis Pharmaceuticals Stock Performance Shares of Apellis Pharmaceuticals stock opened at $29.
98 on Friday. The business’s fifty day simple moving average is $31.02 and its 200-day simple moving average is $36.
94. The company has a quick ratio of 4.18, a current ratio of 4.
36 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.
73 billion, a PE ratio of -14.77 and a beta of 0.87.
Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80.
Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.
32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.
11% and a negative net margin of 34.97%. The business had revenue of $196.
83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the previous year, the company posted ($1.
17) earnings per share. The company’s revenue was up 78.3% on a year-over-year basis.
Insider Buying and Selling In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.
23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000.
This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink .
Insiders own 6.80% of the company’s stock. Institutional Investors Weigh In On Apellis Pharmaceuticals Hedge funds and other institutional investors have recently bought and sold shares of the stock.
Assenagon Asset Management S.A. grew its holdings in shares of Apellis Pharmaceuticals by 191.
9% during the third quarter. Assenagon Asset Management S.A.
now owns 2,144,415 shares of the company’s stock worth $61,845,000 after purchasing an additional 1,409,707 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $32,329,000. Fiera Capital Corp grew its stake in Apellis Pharmaceuticals by 47.
7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after buying an additional 452,753 shares during the last quarter. AQR Capital Management LLC increased its position in Apellis Pharmaceuticals by 337.
3% during the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after buying an additional 190,420 shares during the period. Finally, Redmile Group LLC purchased a new stake in Apellis Pharmaceuticals in the first quarter valued at approximately $9,111,000.
96.29% of the stock is currently owned by institutional investors and hedge funds. Apellis Pharmaceuticals Company Profile ( Get Free Report ) Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Featured Articles Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
